Enclosed herewith announcement pertaining to Dividend declared by the Company at its Board Meeting
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.1 pts more than Nifty Microcap 250 and 19.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Supriya Lifescience's Board declared a final dividend of Rs. 1 per share (50% on Rs. 2 face value), pending shareholder approval at the upcoming AGM. For FY26, the company reported total income of Rs. 8,393.62 million and profit after tax of Rs. 2,091.20 million, up from Rs. 7,063 million and Rs. 1,879.58 million respectively in FY25. EPS grew from Rs. 23.35 to Rs. 25.98, showing an 11% increase in profitability. The standalone audited financial results were approved at the Board meeting held on May 27, 2026, with auditors giving an unmodified opinion.
The dividend declaration signals financial stability and cash generation, with the company growing its bottom line by 11% year-on-year. The Rs. 1 per share payout is consistent with the previous year, indicating reliable returns for shareholders.